Clinical trials: Attention Deficit Disorder (ADD)
Attention Deficit Hyperactivity Disorder, ADHD
Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
The time course of response following one dose of a new methylphenidate hydrochloride extended release capsule is studied in children 6-12 years in a simulated laboratory classroom setting.
- Trial name
- NCT01269463
- Testing
- Methylphenidate Hydrochloride Extended Release Capsule
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit/Hyperactivity Disorder
A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P02 (NCT05721235)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 123 people
- Sponsor
- Corium, Inc.
Attention-Deficit Hyperactivity Disorder(ADHD)
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.
- Trial name
- NCT07086313
- Testing
- EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose
- Where
- Japan
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Attention Deficit Hyperactivity Disorder
Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
The purpose of this study is to evaluate the safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.
- Trial name
- NCT02450890
- Where
- 4 sites in Taiwan
- Volunteers
- 114 people
- Sponsor
- Orient Pharma Co., Ltd.
Attention Deficit Hyperactivity Disorder
PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations
This is PART A of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes implicated in glutamatergic signaling and…
- Trial name
- NCT03265119
- Testing
- AEVI-001
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Attention Deficit Hyperactivity Disorder
Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children
Principal focus is to evaluate the effects of omega 3 fatty acids supplementation on the ADHD children's behaviour during 12 weeks on two years.
- Trial name
- NCT00770627
- Testing
- Omega 3 caps
- Where
- 2 sites in France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Laboratoires URGO
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191737
- Testing
- Atomoxetine
- Where
- 2 sites in Germany
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
The purpose of the study is to investigate the relationship of changes in measures of academic performance and problem behaviors, to changes in core Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in Asian children…
- Trial name
- NCT00471354
- Testing
- Atomoxetine
- Where
- 8 sites in China, South Korea and 1 more
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Lab School Day Study for CONCERTA of Older Children With ADHD
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with attention deficit hyperactivity disorder…
- Trial name
- NCT00799409
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
ADHD
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
This study is a Phase 3, multicenter, dose-optimized, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of oral AK0901 capsules in children 6 to 12 years old with…
- Trial name
- NCT06359899
- Testing
- AK0901 capsule
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Attention Deficit Disorder With Hyperactivity
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
The purpose of this study is to estimate the observed incidence of the health outcomes (suicide attempt or ideation, suicide ideation, suicide attempt, psychosis, and substance abuse) in a cohort of participants diagnosed with…
- Trial name
- NCT04132557
- Testing
- Methylphenidate, Lisdexamfetamine, Atomoxetine
- Where
- United States
- Volunteers
- 430,000 people
- Sponsor
- Janssen Research & Development, LLC
Attention Deficit Hyperactivity Disorder
Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment
The purpose of this study is to evaluate the continued efficacy of modafinil treatment, compared to placebo treatment, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who are responders to…
- Trial name
- NCT00343811
- Testing
- Modafinil
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- Cephalon
Attention Deficit Hyperactivity Disorder (ADHD)
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12…
- Trial name
- NCT01835548
- Testing
- NT0102
- Where
- 4 sites in United States
- Volunteers
- 87 people
- Sponsor
- Neos Therapeutics, Inc
Attention Deficit Hyperactivity Disorder
Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.
This study will compare the safety and efficacy of [S,S]-reboxetine to atomoxetine in the treatment of adult patients with attention deficity-hyperactivity disorder.
- Trial name
- NCT00562055
- Testing
- Atomoxetine, PNU-165442G; [S,S]-reboxetine
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy, safety and to assess the impact of the treatment on quality of life of long-acting methylphenidate in adult participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00783835
- Testing
- Long-Acting Methylphenidate
- Where
- 5 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
ADHD - Combined Type, ADHD Predominantly Inattentive Type
NeuroTrainer Cognitive Training For Academic Focus
This clinical trial aims to evaluate the feasibility and efficacy of NeuroTrainer cognitive training in improving attentional and executive control functions in students with and without attention-related difficulties.
- Conditions
- ADHD - Combined Type, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive
- Trial name
- NCT06512974
- Testing
- NeuroTrainer
- Where
- 3 sites in United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- NeuroTrainer
Attention Deficit Disorder With Hyperactivity
The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate whether familial relationships and psychological status of participants or caregivers as well as Attention Deficit Hyperactivity Disorder (ADHD) symptoms of participants can be improved by…
- Trial name
- NCT00758160
- Testing
- OROS Methylphenidate
- Volunteers
- 296 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Attention Deficit Disorder With Hyperactivity (ADHD)
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.
- Trial name
- NCT07755410
- Testing
- ALKS 7290
- Where
- 28 sites in United States
- Volunteers
- 312 people
- Sponsor
- Alkermes, Inc.
ADHD
Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)
A study to compare the effect of once-daily atomoxetine versus placebo in treating symptoms of ADHD in adults for up to 6 months.
- Trial name
- NCT00190736
- Testing
- Atomoxetine Hydrochloride
- Where
- 19 sites in United States
- Volunteers
- 440 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder, Cannabis Abuse
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse.
- Trial name
- PEACE (NCT00687609)
- Testing
- Atomoxetine
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company